#GI21 ABC06 FOLFOX 6m mOS 2L in mBTC (<1 mo benefit over sx control). Final ClarIDHY and P2 infigratinib results = important to sequence ALL patients with "target rich" BTC!

#GI21 looking forward to this 🤓

Redefining BCLC B, Intermediate-Stage HCC: Is There a Role for Combination Systemic Therapy? @gab9046 Weill Cornell Medicine NewYork-Presbyterian #hpbcsm ow.ly/SSqV50DlSAg

What a great program and great experience FDA Oncology - AACR fellowship. Thank you all for making it a successful educational program. Tons of efforts were put into the program during a difficult time. Kudos for all ⭐️⭐️⭐️⭐️⭐️

with a great panel! laura kulik Vatche G. Agopian and Beau Toskich

Shameless plug -Free Webinar - Multidisciplinary perspectives for HCC! Surgery, IR, Oncology and Hepatology input on HCC using cases. Register Today! conta.cc/3bBgKZ8. Weill Cornell Medicine GI & Hepatology cornellGIcancer Ben Samstein Karim J Halazun MD @gab9046 Anuj Malhotra MD, FSIR, RPVI #livertwitter

great discussion, multidisciplinary care is 🔑! #HCCTAG2021

always enjoy David James Pinato 🇺🇦 commentary discussing hot topics in #hcc #HCCTAG2021

Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta‐Analysis frontiersin.org/article/10.338… NIH cornellGIcancer #livertwitter

#GI22 4⃣/ ✅Immuno💊➕SBRT ➡️IM Chen Abs 554 ⏩84 #pancreaticcancer pts received SBRT (to any met) + nivo (41pts) or ipi/nivo (43pts) 👉6 PRs in the ipi/nivo group 🤔There is something real here Aparna Raj Parikh & @gab9046 had very similar results ‼️This needs to be studied

📘Systemic Therapy for Stage I-III Anal SCC ASCO Journal of Clinical Oncology 🚨Pelvic radiation = cytopenia🔺 ✅Cisplatin-5FU is a non-inferior option, if cisplatin eligible OncoAlert Dr. Cathy Eng #cancer #oncology #MedX

Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505 - Patel - 2025 - Cancer - Wiley Online Library acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… ACS Journal Cancer Syed A. Ahmad Flavio G Rocha, MD, FACS, FSSO PanCAN OncoAlert SWOG Cancer Research Network

Rain or shine, we walk to end pancreatic cancer #PanCANPurpleStride #pancreaticcancer City of Hope City of Hope Surgery

ctDNA-guided adj CTx escalation in stage III CRC #ASCO25 🔎Primary analysis of the ctDNA-positive cohort from the randomized AGITG DYNAMIC-III trial 👉mRFS 29 vs 36 mo 👉CTx escalation does not improve outcome 🧐 ctDNA very helpful to understand risk groups, but we need better

Original Article: Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer (BREAKWATER phase 3 trial) nej.md/3ScDaWC #ASCO25 | ASCO

1st Plenary #ASCO25: #ATOMIC Ph III, adj mFOLFOX + Atezolizumab vs. mFOLFOX in Stg III dMMR colon ca. - 3yr DFS 86.4% vs 76.6% (HR 0.50), benefit seen in all subgroups. DFS 100% in Niche2 - ⬆️ discontinuation w/ Atezo - OS not mature - ⬆️ Gr4 neutropenia - To Adj or to NeoAdj?

I will be making a patient friendly handout for this trial. It will answer the “what else can I do?” I get every visit. Even if benefit is 1% in “real world,” does it matter? Exercise has ASCVD/metabolic benefits way beyond CRC related DFS.